HUMACYTE INC. - COMMON STOCK

Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting

25 Jul 2022 20:26:26 By Nasdaq GlobeNewswire

Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions

19 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

07 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

29 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

27 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries

21 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)

08 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Humacyte to Present at the H.C. Wainwright Global Investment Conference

16 May 2022 08:00:02 By Nasdaq GlobeNewswire

Humacyte First Quarter 2022 Financial Results and Business Update

13 May 2022 07:00:01 By Nasdaq GlobeNewswire

Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

09 May 2022 08:00:02 By Nasdaq GlobeNewswire

Humacyte to Present First Quarter 2022 Financial Results and Provide Recent Corporate Update on May 13, 2022

06 May 2022 08:00:00 By Nasdaq GlobeNewswire

Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer

05 Apr 2022 08:00:03 By Nasdaq GlobeNewswire

Humacyte Announces Date of Annual Shareholder Meeting

04 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update

29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

21 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at Upcoming Investor Conferences in March

01 Mar 2022 08:00:04 By Nasdaq GlobeNewswire

Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis

28 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte to Participate in Fireside Chat at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

09 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios

31 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting

28 Jan 2022 09:15:00 By Nasdaq GlobeNewswire